Dietary Intake and Body Composition in New Users of the Injectable Contraceptive Depot-Medroxyprogesterone Acetate During the First Year of Use

Autor(es)

Silva dos Santos, Priscilla de Nazare ^[1] ; Bahamondes, M. Valeria ^[1] ; Modesto, Waleska Oliveira ^[1] ; Bahamondes, Luis ^[1] ; dos Santos Fernandes, Arlete Maria ^[1]

Afiliação do(s) autor(es)

^[1] Univ Estadual Campinas, Sch Med Sci, Dept Obstet & Gynecol, Human Reprod Unit, Campinas, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF REPRODUCTIVE MEDICINE; v. 62, n. 9-10, p. 526-533, SEP-OCT 2017.
• Citações Web of Science: 2

Resumo

OBJECTIVE: To evaluate dietary intake and body composition in new users of the injectable contraceptive depot-medroxyprogesterone acetate (DMPA). STUDY DESIGN: A non-randomized clinical trial. Healthy women (28 DMPA users and 24 copper intrauterine device {[}IUD] users) were paired for age (1 year) and body mass index (BMI) (kg/m(2)) (1). Weight, lifestyle habits, and dietary intake recorded using a 3-day food recall form were evaluated at three-monthly intervals during the first year of use of the method. Body composition was assessed at baseline and at 12 months by dual-energy x-ray absorptiometry. RESULTS: Mean age was 29.6 and 28.6 years in DMPA and IUD users, respectively, while BMI was 23.9 and 24.5 kg/m(2), respectively. An increase of approximately 12% was found in calorie intake (kilocalories/24 h) and in all the macronutrients of the diet in the DMPA group from the third month onwards. There was increase in total lean mass (p<0.046) in the DMPA group and no statistically significant difference in body weight be tween the groups. No association was found between dietary intake and weight gain. CONCLUSION: When initiating use, new DMPA users should be counseled regarding possible changes in dietary intake. (AU)

• Processo FAPESP: 09/53293-0 - Estudo prospectivo de avaliação da resistência insulínica, metabolismo de lípedes e repercussão subclínica de doença cardiovascular em mulheres que iniciam o uso do contraceptivo injetável trimestal de acetato de medroxiprogesterona de depósito em segmento de 2 anos
• Beneficiário: Luis Guillermo Bahamondes
• Modalidade de apoio: Auxílio à Pesquisa - Pesquisa em Políticas Públicas para o SUS